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Summary
Using computer simulations of a previously published
mathematical model for the regulation of stem cell
and neutrophil production in dogs, we have stud-
ied the efficacy of three different treatment protocols
for cyclical neutropenia involving granulocyte colony
stimulating factor (G-CSF). We used a model based
on canine data to infer treatments for humans be-
cause of the availability of extensive dog data and
the similarity of the dog and human disorders. The
first treatment scheme involves alternate day admin-
istration of G-CSF. The second triggers G-CSF ad-
ministration whenever neutrophil levels fall below a
predetermined level, and the third one follows a ran-
dom administration protocol. The computer simula-
tions predict that clinically desirable results can be
achieved with all three methods, using far less G-
CSF than would be needed with the standard daily
treatment. If the results of this modelling are borne
out clinically, it would entail a considerable financial
savings to patients.
Keywords: cyclical neutropenia, G-CSF treat-
ment, mathematical modelling, non-standard treat-
ment.
Introduction
Cyclical neutropenia (CN) is a rare haematological
disease characterized by oscillations in the circulat-
ing neutrophil count. These levels fall from normal
to barely detectable levels with a typical period of 19
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to 21 days in humans (Guerry et al , 1973; Dale and
Hammond, 1988; Haurie et al , 1998), even though pe-
riods up to 40 days have been observed (Haurie et al ,
1998). These oscillations in the neutrophil count are
generally accompanied by oscillations around normal
levels in other blood cell lineages such as platelets,
lymphocytes and reticulocytes (Haurie et al , 1998,
2000). All grey collies (Lund et al , 1967) are born
with this congenital disease and oscillations with pe-
riod on the order of 11 to 16 days are observed (Hau-
rie et al , 1998, 1999b, 2000). This animal model has
provided extensive experimental data to decipher the
nature of CN.
Many mathematical models have been proposed
to explain the origin of these oscillations as well as
to understand the control of neutrophil production
in non-pathological cases. For a discussion of previ-
ous models that have been developed see Hearn et al
(1998) and Haurie et al (1998). In a recent study
(Bernard et al , 2003), it was shown that all of the
characteristics of CN in grey collie can be accounted
for by an elevated level of cellular death (apopto-
sis) in the neutrophil precursors. This elevation of
apoptosis in CN was first predicted over twenty years
ago (Mackey, 1978) and has been observed clinically
(Aprikyan et al , 2001). The modelling predicts that
decreasing the level of apoptosis in neutrophil pre-
cursors can attenuate or eliminate many of the symp-
toms of CN.
CN is often treated using granulocyte colony stimu-
lating factor (G-CSF) (Hammond et al , 1989) which
is known to interfere with apoptosis (Koury, 1992;
Park, 1996; Williams et al , 1990; Williams and Smith,
1993). Treatment protocols (Amer. Soc. Clin. On-
col., 1997) typically call for daily subcutaneous in-
jection of G-CSF at 5 µg per kg of body weight,
and for a 60 kg adult this currently entails a yearly
cost of approximately US$40,000 (CF: Check D.C.
Dale reference for other dosage AM.J Hema-
tol. 2003). Clearly it would be of enormous help if
the same clinical effects could be achieved with the
use of less G-CSF. A few alternative treatment strate-
gies have been reported in which various administra-
tion schemes have been used (Jayabose and Sandoval,
1994; Dicato et al , 1992; Danielson and Harmenberg,
1992), yet no attempt to use current knowledge of
the dynamic behaviour of the haematopoietic system
for designing new treatment protocols has apparently
been made.
This paper uses the recent model of Bernard et al
(2003) to examine, through computer simulations,
the predicted effects of different protocols for the ad-
ministration of G-CSF to grey collies. The goal is to
see whether one can find ways of administering G-
CSF less frequently than daily and still achieve the
same clinical effect currently reached using a daily
regimen. In the first section, we describe the model
for cyclical neutropenia and its dynamic character-
istics. Second, we illustrate the computer predicted
results of three different schemes for the administra-
tion of G-CSF. The first involves giving G-CSF every
other day. The second is a “threshold triggered deci-
sion” in which G-CSF is administered whenever the
neutrophil count falls below a predetermined value.
Finally, the third scheme is a random delivery proto-
col. The paper concludes with a brief discussion.
The Model
The model used in this paper considers two cell types
whose dynamics are regulated by negative feedback
loops. These cell types are the haematopoietic stem
cells (HSCs) and the mature neutrophils. HSCs
are assumed to be self-renewing and multi-potential.
That is, HSCs are self-sustained and newly divided
cells can either remain in the HSC pool, or be trig-
gered to undergo differentiation into any of the blood
cell lineages.
Fig 1. illustrates the two components of this model:
the HSC compartment and the mature neutrophil
compartment. The rate at which HSCs differenti-
ate into the neutrophil lineage is assumed to be de-
termined by the blood G-CSF level. As these neu-
trophil precursors differentiate, their number is am-
plified through successive divisions.
As shown in Fig 1., there are two feedback loops.
The first loop, between the mature neutrophil com-
partment and the HSC compartment, is the rate
(F (N)) of HSC differentiation into the neutrophil lin-
eage. F (N) is mediated by G-CSF levels and oper-
ates with a lag of duration τN that accounts for the
time required for neutrophil precursor division and
maturation.
The second feedback loop regulates the rate (K(S))
at which HSCs enter the proliferative cycle from
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Fig 1: G-CSF mediated neutrophil differentiation.
the resting (G0) state. It operates with a delay
τS that accounts for the cell cycle duration, that is
the length of time required to produce two daughter
HSCs from one mother cell. K(S) regulates the level
of haematopoietic stem cells, while F (N) controls the
neutrophil count.
G-CSF acts on model parameters in various ways.
First, it decreases the apoptosis rate of neutrophil
precursors and HSCs, leading to an increase of HSC
levels and neutrophil amplification (Basu et al , 2002).
Second, it increases the differentiation rate F of HSC
into the neutrophil precursor lineage. Third, the
HSC cell cycle duration and the neutrophil precursor
transit time are decreased. G-CSF is partly cleared
through binding to neutrophil receptors. Thus, G-
CSF clearance decreases as the number of neutrophils
decreases (Kearns et al , 1993; Terashi et al , 1999) and
the neutrophil count increases when the level of G-
CSF is increased (Petros, 1992; Chatta et al , 1994;
Price et al , 1996). This type of regulation regulation
is a negative feedback mechanism. A similar mecha-
nism is assumed to be in place to control HSC levels,
and we take K(S) to be also a negative feedback loop.
In the context of the mathematical modelling, this
interaction has been kept as simple as possible to
make model-based predictions possible. The equa-
tions of the model are presented in Appendix A.
Behaviour of the model
The model predicts that for elevated apoptosis rates,
oscillations in both the HSC and neutrophil popula-
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tions appear (Bernard et al , 2003). More interest-
ingly, it was shown that for wide parameter range,
the system displays bistability. In this case, depend-
ing on the history of neutrophil and HSC levels, the
neutrophil count may either oscillate or stabilize to
a steady state. This bistability phenomenon sug-
gests a potential neutrophil count or phase-dependent
treatment on neutrophil levels. Although there is no
experimental evidence that bistability really occurs
in CN patients, some experimental records (Haurie
et al , 1999b) display different responses to G-CSF
treatment applied at different times.
Fig 2. shows the absolute neutrophil count (ANC)
from a grey collie over 712 days. Two phases of con-
tinuous G-CSF treatment were applied (day 0 to day
96 and day 296 to day 436). The two phases without
treatment show significant differences in the ampli-
tude of oscillation of ANC and periodicities. Spec-
tral analysis using the Lomb periodogram (a gen-
eralization of Fourier spectral analysis for unevenly
sampled data) has proven to be useful for analysis of
periodic haematological diseases (Fortin and Mackey,
1999; Haurie et al , 1999a). We applied the Lomb pe-
riodogram technique to the two phases without treat-
ment. Phase 1 (day 96 to 296) has a period of 14.6
days with strong significance p ≤ 10−5. Phase 2
also shows some periodicity to the eye (period 15.4
days) but it is not significant. This clear change in
the neutrophil dynamics may indicate that the sec-
ond G-CSF treatment stabilized the neutrophil level,
whereas the first phase of treatment did not. Such
bistability, if true, would suggest that the neutrophil
count can either display periodic fluctuations with
large amplitude or stabilize around an average value.
In this paper, based on computer simulations we show
how the timing of the treatment affects the behaviour
of the ANC.
Investigating administration patterning
Daily G-CSF treatment generally results in a marked
increase in average neutrophil count and an elevation
in the nadir counts, decreasing the duration of severe
neutropenia. An absolute neutrophil count (ANC)
below 0.5×109 cell/L usually defines neutropenia. In
investigating different patterning of G-CSF adminis-
tration with this mathematical model, the number of
days of neutropenia in a cycle serve as a benchmark
for evaluating efficiency of different treatment strate-
gies.
The mathematical model describes 2 dynamical
variables and contains 11 physiological parameters,
including 2 time delays. The detailed description of
the model is presented in Appendix A. By varying
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Fig 2: (A) Absolute neutrophil count from a grey col-
lie (Oprah, data generously supplied by Prof. David C.
Dale). The red bars show periods of continuous G-CSF
treatment. Notice the periodicity in region 1 versus re-
gion 2. (B) and (C) show the corresponding Lomb peri-
odograms of phases 1 and 2 respectively.
some of the parameters, we can simulate the effects
of G-CSF administration in CN. In Appendix B, we
explain how we mimicked the administration of G-
CSF as well as the numerical methods that have been
used.
The effects of non-standard G-
CSF delivery protocols
To study the effects of non-standard delivery pro-
tocols for G-CSF, we compared a daily administra-
tion protocol with alternate day, neutrophil-level-
dependent and random administration protocols. For
each scheme, computer simulations were performed
over 70 days (5 cycles of 14 days). In each case, we
computed the solution for every starting day in the
cycle (14 runs for each treatment scheme). The aver-
age number of neutropenic days as well as the average
number of days of treatment are reported in Table I.
Daily G-CSF administration is generally associated
with an increase of the amplitude and a decrease of
the period of the oscillations (Haurie et al (1999a)).
However, it has also been reported that in some iso-
lated cases G-CSF therapy abolished significant oscil-
lations (Haurie et al (1999a), Hammond et al (1989)).
Computer simulations of the model predict that daily
administration of G-CSF could either lead to large
amplitude oscillations with reduced period of neu-
tropenia, or stabilization of the ANC above the neu-
tropenic level (average of 1.45×109cell/L, see Fig 3.).
We found that the type of response depends on the
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Fig 3: Stabilization of an oscillatory neutrophil count
when starting the daily treatment right after the begin-
ning of the falling phase of oscillation.
neutrophil level on the first day of treatment. This
suggests that the starting date of the treatment will
affect the behaviour of the neutrophil count. For
daily and alternate day therapies, this bistability can
be characterized in terms of starting day of the treat-
ment (see Fig 4.) and both behaviours (stabilization
and oscillations) are distinguished in Table I. The
treatment would be optimal when the mathematical
model predicts a stabilization of the ANC, as shown
in Fig 4. From our numerical simulations, if day
0 represents the day in the cycle at which the ANC
nadir occurs, the optimal phase for starting the treat-
ment is between day 3 and day 8 for a cycle length
of 14 days. Moreover, the model predicts that start-
ing the treatment during the neutropenic phase (days
0–1 and days 12–13) will lead to large oscillations.
Alternate day delivery
In the every-other-day therapy, the model predicts
that the blood neutrophil level when G-CSF admin-
istration starts (and hence, the starting day of the
treatment) also has an effect on the behaviour of the
neutrophils. However, because the treatment is in-
terrupted every two days, the behaviour of the neu-
trophil count is influenced by the ANC every time
G-CSF is injected. Consequently, a more erratic
response results, but having the same general be-
haviour, and we can still distinguish a stabilization
and an oscillatory phase (see Fig 4. and Fig 5. which
shows a predicted stabilization behaviour following
the cessation of treatment). In this case, the solu-
tion is said to be in the stabilization phase if the
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Fig 4: Effect of starting day of treatment for cycles with
a period of 14 days using the daily and alternate day
schemes. Ideal starting day of treatment (in the stabi-
lization phase) is between day 3 and day 8.
ANC remains between 0.7 and 2.3 ×109 cells/L. The
range of ideal starting days is as broad as for daily G-
CSF administration, and this scheme also efficiently
increases the nadir of the neutrophil level and short-
ens the period of neutropenia. Therefore, it seems
to achieve positive results similar to daily G-CSF. In
particular, one can see from Table I that the results
for alternate-day treatment during the stabilization
phase are better than the results for the oscillating
period of the daily scheme. This suggests that if one
is able to localize the stabilization phase for a sub-
ject, then starting every-other-day treatment in this
period would have similarly good results as contin-
uous G-CSF administration in the oscillatory phase.
And more importantly, it uses half the amount of G-
CSF.
Threshold triggered delivery
To determine the effects of threshold triggering drug
delivery, we simulated G-CSF administration when-
ever the ANC falls below a predetermined level. Re-
sults for levels 0.7, 0.9 and 1.2×109cell/L are shown
in Table I. The bistability in the parameter space
was still present in the results, but there was no obvi-
ous distinction between a stabilization and oscillatory
phase as a function of starting day of treatment, as for
the alternate day and daily schemes (see Fig 6.). This
protocol targets specific days when G-CSF is needed
and, as a result, it seems that its efficiency is good
with respect to both number of neutropenic days and
number of treatment days, especially for high prede-
termined levels (see for instance level 1.2 ×109cell/L
in Table I). Although this scheme presents very in-
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Fig 5: Simulation of the ANC and HSC count using an
alternate day regimen, representing a stabilization (the
ANC remains between 0.7 and 2.3 ×109 cells/L). Note the
low level neutrophil oscillations following the cessation of
treatment.
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Fig 6: Simulation of the ANC and HSC count using a
neutrophil level dependent regimen (threshold level =
0.7×109 cell/L). Over a treatment period of 70 days, there
were 35.7% days of G-CSF administration and 5.7% days
of neutropenia.
teresting theoretical results, it is not a practical ap-
proach since it would require monitoring of the blood
count frequently and hence, involves expensive labo-
ratory work.
Random protocol
The results obtained with the level dependent scheme
justify finding a scheme that would give similar re-
sults, but that would be more easily implemented.
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Fig 7: Example of the effects of the random protocol
where there were 70% of treatment days.
We consider a random protocol in which G-CSF is ad-
ministered randomly for a predetermined number of
days. In particular, we use the number of days of ad-
ministration obtained in the level dependent method
as a first indicator (average of 53.8% of treatment
days for level 1.2×109cell/L). However, because the
random protocol is obviously not as targeted as the
level-dependent scheme, it appears that the number
of days of treatment must be higher than for thresh-
old triggered therapy to achieve analogous results.
We simulated random administration of G-CSF dur-
ing 70 days for two cases (50% and 70% of treatment
days) (see Fig 7.). Because the random protocol does
not necessarily administrate G-CSF the first day of
treatment, we only made simulations for starting day
0 and 5 (in the oscillatory and stabilization phase re-
spectively). In each case, we carried out 12 runs and
averaged the results, presented in Table I. The pro-
tocol with 50% of treatment days did not give good
results. However, the results for the protocol with
70% of treatment days give similar results as the al-
ternate day therapy. Table I gives a summary of all
the methods and their results.
Discussion
Cyclical neutropenia has been extensively modelled
in dogs due to its interesting dynamics and the avail-
ability of extensive data for grey collies. However,
there have been no attempt to use its dynamic fea-
tures to improve existing treatment strategies. Us-
ing a mathematical model based on canine data, we
have provided a computer simulation study of three
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Protocol Neutr. Days of
days (%) Treatment (%)
No Treatment 34.3 0.0
Daily 3.2 (3.4) 100.0 (0.0)
Stabilization 0.0 (0.0) 100.0 (0.0)
Oscillations 5.6 (2.5) 100.0 (0.0)
Alternate Day 4.4 (4.2) 50.0 (0.0)
Stabilization 0.0 (0.0) 50.0 (0.0)
Oscillations 7.3 (2.8) 50.0 (0.0)
Level Dependent
level = 0.7 6.3 (2.6) 37.9 (2.6)
level = 0.9 3.0 (2.5) 47.6 (2.3)
level = 1.2 1.1 (1.7) 53.8 (4.5)
Random
50% Treat. D. 13.0 (7.5) 50.0 (0.0)
70% Treat. D. 7.9 (4.1) 70.0 (0.0)
Table I: Summary of the different protocols. Val-
ues represent means, and standard deviations are in
parentheses. For the level dependent protocol, levels
are in ×109cell/L.
treatment protocols that achieve essentially the same
results as daily administration of G-CSF but with
smaller total G-CSF levels and/or fewer days of ad-
ministration. The first treatment scheme is the al-
ternate day (or every-other-day) regimen, which in-
creases the nadir of the neutrophil level to clinically
acceptable levels. The second proposed treatment
protocol, neutrophil level-dependent administration,
in its current form would be difficult to implement,
but an alternative random treatment scheme could
easily be designed to achieve similar results. Mim-
icking the G-CSF administration pattern that was
obtained by computer simulation is a possibility that
should be considered. However, because there may
be some subtle differences between the dog model and
the human disease, clinical trials will be necessary to
establish efficacy of the treatments in humans.
Moreover, the existence of a region of bistability
could be exploited by perturbing the haematopoietic
system to stabilize ANC levels. If this were possible,
cyclic neutropenia could be triggered into intermit-
tent phases of low level oscillatory, or non-oscillatory,
behaviour (c.f. Fig 5. for an example) and only oc-
casional doses of G-CSF would then be required to
maintain this state. This idea of using a “physiolog-
ical black hole” to trigger or destroy oscillations was
originally put forward by Winfree (1973, 1980) in a
different context.
Because of the oscillatory nature of cyclical neu-
tropenia and the nonlinear interactions between G-
CSF and circulating neutrophils through clearance
processes, this disorder is a good candidate for design-
ing dynamic treatment protocols. We have shown,
based on a computer simulated model, that phase-
dependent protocols should be able to achieve equal
or better results than standard protocols, while using
less G-CSF for fewer days of treatment. Obviously,
this result opens up the possibility of decreasing side-
effects as well as increasing the cost-effectiveness of
the treatment, thereby improving the quality of life
for patients.
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Appendix A. Mathematical
model
The model for neutrophil production consists of a sys-
tem of two delay differential equations (DDEs). Each
equation considers the net production and loss rates
(termed P (t) and L(t) respectively) of haematopoi-
etic stem cells and mature neutrophils.
dS(t)
dt
= PS(t)− LS(t), (1)
dN(t)
dt
= PN (t)− LN (t). (2)
The net production rates are:
PS(t) = 2e−γSτSS(t− τS)K(S(t− τS)), (3)
PN (t) = AS(t− τN )F (N(t− τN )). (4)
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The delayed arguments account for the time required
for cell division cycles and maturation to occur. The
net loss rates are:
LS = S(t)[F (N(t)) +K(S(t))], (5)
LN = αN(t). (6)
The variable S represents the number of haematopoi-
etic stem cells in the resting (G0) phase. Cells in the
resting phase can either enter the proliferative phase
at a rate K(S) or differentiate at a rate F (N) to ul-
timately give rise to mature neutrophils, represented
by the second variable, N . Cells in the HSC prolifera-
tive phase undergo apoptosis at a rate γS and the cell
cycle duration is τS . The fraction of HSC surviving
cell division is then exp(−γSτS). Successive divisions
amplify cell numbers in the differentiation pathway
by a factor A, which is also used to account for cell
loss due to apoptosis. After a time τN , each differ-
entiated HSC gives rise to A mature neutrophils N ,
which are released into the circulation. It is assumed
that mature neutrophils are eliminated at a rate α.
Two feedback loops control the entire process
through the neutrophil differentiation rate F (N) and
the HSC proliferation rate K(S). G-CSF mediates
neutrophil differentiation through a clearance mecha-
nism. When neutrophil count decreases, C-CSF level
goes up due to the lack of clearance and differentia-
tion increases. As a function of the neutrophil count,
the differentiation rate is thus monotonically decreas-
ing (here G-CSF is implicitly taken into account), and
is described by a decreasing Hill function,
F (N) = f0
θn1
θn1 +Nn
, (7)
where f0 is the maximal differentiation rate (i.e. in
absence of neutrophil), n is a cooperativity coefficient
and θ1 is the neutrophil concentration at which differ-
entiation is half maximal. Notice that θ1 depends on
endogenous G-CSF production and G-CSF adminis-
tration. HSC proliferation is assumed to be regulated
through a similar mechanism. When the HSC level
is depleted, intercellular signals trigger cell replica-
tion. These signals become fainter when HSC level
increases back to normal levels. The HSC prolifera-
tion rate feedback term is thus also described by a
decreasing Hill function,
K(S) = k0
θs2
θs2 + Ss
. (8)
The parameter k0 is the maximal proliferation rate, s
is a cooperativity coefficient and θ2 the HSC concen-
tration at which HSC proliferation is half maximal.
See Bernard et al (2003) for a detailed derivation of
the feedback functions.
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Fig 8: Model of neutrophil production. The variable S
represents the number of haematopoietic stem cells in the
resting (G0) phase. Cells in the resting phase can either
enter the proliferative phase at a rate K(S) or differen-
tiate at a rate F (N) to ultimately give rise to mature
neutrophils N , the second variable. Cells in the HSC
proliferative phase undergo apoptosis at a rate γS and
the cell cycle duration is τS . Successive divisions amplify
cell number in the differentiation pathway by a factor A,
which is also used to account for cell loss due to apopto-
sis. After a time τN , differentiated cells become mature
neutrophils N and are released into the blood. It is as-
sumed that mature neutrophils die at a fixed rate α. Two
feedback loops control the entire process through the pro-
liferation rate K(S) and the differentiation rate F (N).
Appendix B. Simulating CN and
G-CSF administration
Bernard et al (2003) showed that the model can pre-
dict cyclical neutropenia and simulate G-CSF admin-
istration by using physiologically relevant values for
the 11 different parameters. The parameters used for
numerical simulation are those presented in Bernard
et al (2003) and they are in agreement with experi-
mental data. Table II presents the parameter values
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used for mimicking the neutrophil production in three
situations of interest: in a healthy subject (without
CN), in a dog suffering from CN, and under G-CSF
treatment. For more details on the choice and esti-
mation of those parameters, see Bernard et al (2003).
Numerical simulations were performed using the
DDE solver dde23 (Shampine and Thompson, 2001)
for Matlab, which solves delay differential equations
with constant delays. Mimicking G-CSF injection
in a cyclic neutropenic subject was done by simply
changing the corresponding sets of parameters. Five
parameters were modified under the influence of G-
CSF: the neutrophil amplification A, the HSC apop-
tosis rate γS , the half-differentiation level θ1, the cell
cycle duration τS and the maturation transit time τN .
We first computed the solution with the CN param-
eters for a transient period of 200 days. This allowed
the system to settle down to the stable periodic solu-
tion and gives a good approximation of the behaviour
in the CN situation. Then, administration of G-CSF
was simulated by solving the system using the set
of parameters corresponding to G-CSF. For instance,
to simulate the alternate day treatment, we first in-
tegrated the DDE system using the CN parameters
for one day. Then, we integrated the equations us-
ing the G-CSF parameters for the next day, and we
kept switching from one parameter set to the other
during the desired simulated treatment period. Note
that the values of the delays are modified to mimic
G-CSF. Because dde23 only allows constant delays,
this leads to assumptions on G-CSF kinetics since we
could not simulate a gradual decrease in the time de-
lays and the other parameter values when switching
from CN to G-CSF. This corresponds to assuming
that the effects of G-CSF are immediate when in-
jected, and that those effects last exactly one day
before disappearing completely and instantaneously.
Parameter Unit Health CN G-CSF
A 100 380 10 20
f0 day−1 0.8 0.8 0.8
θ1 108 cell/kg 0.36 0.36 0.8
k0 day−1 8.0 8.0 8.0
θ2 106 cell/kg 0.095 0.095 0.095
n - 1 1 1
s - 2 2 2
τN day 3.5 3.5 3.0
τS day 2.8 2.8 2.6
γS day 0.07 0.07 0.05
α day−1 2.4 2.4 2.4
Table II: Estimated model parameters used for nu-
merical simulations of healthy condition, cyclical neu-
tropenic condition and under G-CSF treatment. Val-
ues from Bernard et al (2003).
9
